Brief: Lyell Immunopharma Reports Business Highlights And Financial Results For The Fourth Quarter And Full Year 2022
28/02/2023 22:27
Feb 28 (Reuters) - Lyell Immunopharma Inc LYEL.O :
* LYELL IMMUNOPHARMA REPORTS BUSINESS HIGHLIGHTS AND
FINANCIAL
RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2022
* LYELL IMMUNOPHARMA INC - CASH, CASH EQUIVALENTS AND
MARKETABLE
SECURITIES OF $710.3 MILLION AS OF DECEMBER 31, 2022 SUPPORTS
ADVANCING PIPELINE INTO 2026
* LYELL IMMUNOPHARMA INC - QTRLY REVENUE WAS $48.4 MILLION
Source text for Eikon: ID:nGNX8f2fkG
Further company coverage: LYEL.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Lyell Immunopharma
See all newsBrief: Lyell Immunopharma Says Additional Clinical Data And End-Of-Phase 1 FDA Meeting Expected In 2027
Lyell Immunopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary
Lyell Immunopharma, Inc. expected to post a loss of $2.08 a share - Earnings Preview
Brief: Lyell Immunopharma Q2 Operating Expenses USD 47.341 Million
Brief: Lyell Immunopharma Shows Updated Safety Data For Ronde-Cel In Patients With Large B-Cell Lymphoma